等待開盤 10-01 09:30:00 美东时间
-2.160
-2.30%
今日重点评级关注:HC Wainwright & Co.:维持GoldMining"买入"评级,目标价从3.25美元升至3.75美元;摩根士丹利:维持Crinetics Pharmaceuticals"超配"评级,目标价从65美元升至77美元
09-30 14:16
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从9美元升至9.25美元;JMP证券:维持Crinetics Pharmaceuticals"跑赢大市"评级,目标价从86美元升至143美元
09-29 09:15
There’s a lot to be optimistic about in the Technology sector as 2 analysts jus...
09-26 20:20
There’s a lot to be optimistic about in the Technology sector as 2 analysts jus...
09-26 19:50
BTIG analyst Gray Powell reiterates Okta (NASDAQ: OKTA) with a Buy and maintains $142 price target.
09-26 18:09
Mad Money's Jim Cramer takes a look at CMS Energy, Ramaco Resources, Accenture, Okta and Rocket Companies.
09-22 20:09
Shares of Zscaler (NASDAQ:ZS) rose about 2% premarket on Wednesday after fourth-quarter results and guidance exceeded expectations which also saw positive reactions from analysts. BTIG reiterated its ...
09-03 20:01
Although Okta offers a fundamentally relevant narrative, the wild trading of OKTA stock warrants a nuanced options strategy.
08-30 03:53
近一个月的 AI 应用赛道,像被按下了 “质疑键”。 从8月7日GPT-5发布后“模型跑太快、应用跟不上”的讨论,到8月19日香橼做空Palant...
08-29 18:15
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Okta (OKTA)业绩会实录,我总结如下:</p> <p>• 财务业绩: - 第二财季总收入同比增长10%-11% - 第二财季非GAAP营业利润率为25%-26% - 第二财季非GAAP自由现金流利润率约为28% - 截至第二财季末,公司持有29亿美元现金、现金等价物和短期投资</p> <p>• 财务指标变化: - 净留存率(NRR)在第二财季稳定在106% - 大于100万美元年度合同价值(ACV)的客户数量增长15%,达到495家 - 大于10万美元年度合同价值(ACV)的客户数量有所增加 - 第二财季创造了历史
08-29 12:14